KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Land & Improvements (2016 - 2018)

Teva Pharmaceutical Industries' Land & Improvements history spans 7 years, with the latest figure at $351.0 million for Q4 2018.

  • For the quarter ending Q4 2018, Land & Improvements fell 10.0% year-over-year to $351.0 million, compared with a TTM value of $351.0 million through Dec 2018, down 10.0%, and an annual FY2018 reading of $351.0 million, down 10.0% over the prior year.
  • Land & Improvements for Q4 2018 was $351.0 million at Teva Pharmaceutical Industries, down from $361.0 million in the prior quarter.
  • The five-year high for Land & Improvements was $439.0 million in Q4 2016, with the low at $351.0 million in Q4 2018.
  • Average Land & Improvements over 5 years is $379.9 million, with a median of $373.0 million recorded in 2014.
  • Year-over-year, Land & Improvements decreased 16.59% in 2014 and then rose 11.42% in 2016.
  • Tracing TEVA's Land & Improvements over 5 years: stood at $372.0 million in 2014, then grew by 5.91% to $394.0 million in 2015, then increased by 11.42% to $439.0 million in 2016, then dropped by 11.16% to $390.0 million in 2017, then dropped by 10.0% to $351.0 million in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Land & Improvements are $351.0 million (Q4 2018), $361.0 million (Q3 2018), and $374.0 million (Q2 2018).